Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series
K Holbrook, J Lutzky, MA Davies, JM Davis, IC Glitza… - Cancer, 2020 - Wiley Online Library
Background Sixty percent of patients with stage IV melanoma may develop brain
metastases, which result in significantly increased morbidity and a poor overall prognosis …
metastases, which result in significantly increased morbidity and a poor overall prognosis …
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
K Holbrook, J Lutzky, MA Davies, JM Davis… - Cancer, 2019 - scholarship.miami.edu
All clinical trials to date with encorafenib and binimetinib (US Food and Drug Administration–
approved in June 2018 for BRAF‐mutated metastatic melanoma) have excluded untreated …
approved in June 2018 for BRAF‐mutated metastatic melanoma) have excluded untreated …
[HTML][HTML] Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
K Holbrook, J Lutzky, MA Davies, JM Davis, IC Glitza… - Cancer, 2020 - ncbi.nlm.nih.gov
Background Sixty percent of patients with stage IV melanoma may develop brain
metastases, which result in significantly increased morbidity and a poor overall prognosis …
metastases, which result in significantly increased morbidity and a poor overall prognosis …
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
K Holbrook, J Lutzky, MA Davies, JM Davis… - …, 2020 - mdanderson.elsevierpure.com
Background: Sixty percent of patients with stage IV melanoma may develop brain
metastases, which result in significantly increased morbidity and a poor overall prognosis …
metastases, which result in significantly increased morbidity and a poor overall prognosis …
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
K Holbrook, J Lutzky, MA Davies, JM Davis, IC Glitza… - Cancer, 2019 - europepmc.org
BACKGROUND: Sixty percent of patients with stage IV melanoma may develop brain
metastases, which result in significantly increased morbidity and a poor overall prognosis …
metastases, which result in significantly increased morbidity and a poor overall prognosis …
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
K Holbrook, J Lutzky, MA Davies, JM Davis… - Cancer, 2020 - pubmed.ncbi.nlm.nih.gov
Background Sixty percent of patients with stage IV melanoma may develop brain
metastases, which result in significantly increased morbidity and a poor overall prognosis …
metastases, which result in significantly increased morbidity and a poor overall prognosis …